bp102
Colorectal Cancer Metastatic
Fudan UniversityPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
64 Active assets in the Colorectal Cancer Metastatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Binimetinib Pierre Fabre Medicament | Phase 3 | BB |
Irinotecan Oncolytics Biotech | Phase 4 | BB |
Aflibercept Sanofi | Phase 3 | BB |
Inno-206 Northwell Health | Phase 4 | B |
Durvalumab University of Iowa | Phase 2 | B |
View all 50 →
Same molecule, other indications
bp102 is also rated in:
Advanced or Metastatic Non-squamous Non-small Cell Lung CancerDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →